OBJECTIVE: The objective of this study was to identify clinical and dosimetric factors for the development of radiation pneumonitis (RP) among patients with oesophageal cancer treated with three-dimensional radiotherapy without prophylactic nodal irradiation. METHODS: 125 patients with oesophageal cancer had undergone dose-volume histogram (DVH) metrics and received chemoradiotherapy (CRT). Several clinical and dosimetric factors with regard to the lung were evaluated as predictive factors for the development of symptomatic RP. RESULTS: 26 patients (20.8%) developed symptomatic RP classified as greater than or equal to Grade 2. By univariate analysis, body weight loss, tumour length, Stage IV, response to treatment and all DVH parameters proved to be significant factors for the development of RP (p < 0.05). By multivariate analysis, Stage IV and all dosimetric factors were independent predictive factors for the development of symptomatic RP (p < 0.05). Recursive partitioning analysis indicated that V10 values of 24.8% or more and Stage IV were associated with higher development of RP (odds ratio 6.53). CONCLUSIONS: Our study demonstrated that severe RP was also developed in patients treated with the minimal radiation field. Stage IV and the dosimetric factors were identified as independent predictive factors for symptomatic RP in oesophageal cancer patients treated with CRT without prophylactic nodal irradiation.
OBJECTIVE: The objective of this study was to identify clinical and dosimetric factors for the development of radiation pneumonitis (RP) among patients with oesophageal cancer treated with three-dimensional radiotherapy without prophylactic nodal irradiation. METHODS: 125 patients with oesophageal cancer had undergone dose-volume histogram (DVH) metrics and received chemoradiotherapy (CRT). Several clinical and dosimetric factors with regard to the lung were evaluated as predictive factors for the development of symptomatic RP. RESULTS: 26 patients (20.8%) developed symptomatic RP classified as greater than or equal to Grade 2. By univariate analysis, body weight loss, tumour length, Stage IV, response to treatment and all DVH parameters proved to be significant factors for the development of RP (p < 0.05). By multivariate analysis, Stage IV and all dosimetric factors were independent predictive factors for the development of symptomatic RP (p < 0.05). Recursive partitioning analysis indicated that V10 values of 24.8% or more and Stage IV were associated with higher development of RP (odds ratio 6.53). CONCLUSIONS: Our study demonstrated that severe RP was also developed in patients treated with the minimal radiation field. Stage IV and the dosimetric factors were identified as independent predictive factors for symptomatic RP in oesophageal cancerpatients treated with CRT without prophylactic nodal irradiation.
Authors: P Wong; A N Leung; G J Berry; K A Atkins; J G Montoya; S J Ruoss; F E Stockdale Journal: AJR Am J Roentgenol Date: 2001-03 Impact factor: 3.959
Authors: M L Hernando; L B Marks; G C Bentel; S M Zhou; D Hollis; S K Das; M Fan; M T Munley; T D Shafman; M S Anscher; P A Lind Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: A Ohtsu; N Boku; K Muro; K Chin; M Muto; S Yoshida; M Satake; S Ishikura; T Ogino; Y Miyata; S Seki; K Kaneko; A Nakamura Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Weili Wang; Martha M Matuszak; Chen Hu; Ke Colin Huang; Eileen Chen; Douglas Arenberg; Jeffrey L Curtis; Shruti Jolly; Jian-Yue Jin; Mitchell Machtay; Randall K Ten Haken; Feng-Ming Spring Kong Journal: Int J Radiat Oncol Biol Phys Date: 2020-05-26 Impact factor: 7.038
Authors: Stefan Münch; Sylvia Aichmeier; Alexander Hapfelmeier; Marciana-Nona Duma; Markus Oechsner; Marcus Feith; Stephanie E Combs; Daniel Habermehl Journal: Strahlenther Onkol Date: 2016-07-14 Impact factor: 3.621
Authors: Yaqin Zhao; Lu Chen; Shu Zhang; Qiang Wu; Xiaoqin Jiang; Hong Zhu; Jin Wang; Zhiping Li; Yong Xu; Ying Jie Zhang; Sen Bai; Feng Xu Journal: Thorac Cancer Date: 2015-01-07 Impact factor: 3.500